Brief: Matinas Biopharma Provides Business Update And 2023 Strategic Outlook

Matinas BioPharma Holdings

30/01/2023 22:01

Jan 30 (Reuters) - Matinas BioPharma Holdings Inc
 MTNB.A :
    * MATINAS BIOPHARMA PROVIDES BUSINESS UPDATE AND 2023
STRATEGIC
OUTLOOK
    * MATINAS BIOPHARMA HOLDINGS INC - ENDED 2022 WITH
APPROXIMATELY
$28.8 MILLION, SUFFICIENT TO FUND PLANNED OPERATIONS INTO Q2
2024
    * MATINAS BIOPHARMA HOLDINGS - PRIORITIZATION ON BUILDING
EXTERNAL
PARTNERSHIPS AND AN INTERNAL PIPELINE CENTERED ON GENE THERAPIES
AND NUCLEIC ACIDS
    * MATINAS BIOPHARMA HOLDINGS INC - COLLABORATIONS WITH
BIONTECH
AND NATIONAL RESILIENCE EXPECTED TO GENERATE INITIAL IN VIVO
DATA IN 1H 2023
    * MATINAS- SEEKING BARDA FINANCIAL SUPPORT & FDA FEEDBACK ON
PHASE
3 STUDY IN INVASIVE FUNGAL INFECTIONS OF MAT2203 PRIOR TO
COMMENCING PHASE 3 PROGRAM

Source text for Eikon:  ID:nGNX4mXFrL 
Further company coverage:  MTNB.A 
 ((Reuters.Briefs@thomsonreuters.com;))